

Table 7. MIC and zone diameter breakpoints for *Acinetobacter* species

Antibiotic	MIC breakpoint (mg/L)			Disc content (µg)	Interpretation of zone diameters (mm)			Comment
	R >	I	S ≤		R ≤	I	S ≥	
Aminoglycosides								
Gentamicin	4	-	4	10	19	-	20	
Penicillins								
Piperacillin/tazobactam	16	-	16	75/10	21	-	22	No EUCAST MIC BP as there is insufficient clinical evidence. BSAC data used.
Carbapenems								
Doripenem	4	2-4	1	10	14	15-21	22	
Imipenem	8	4-8	2	10	13	14-24	25	
Meropenem	8	4-8	2	10	12	13-19	20	
Quinolones								
Ciprofloxacin	1	-	1	1	20	-	21	
Miscellaneous antibiotics								
Colistin	2	-	2	-	-	-	-	Disc diffusion susceptibility testing is unreliable because of the high rate of false susceptibility. An MIC method is therefore recommended.
Tigecycline								No EUCAST MIC BP as there is insufficient clinical evidence. For determining susceptibility a gradient method should be used and the EUCAST Non-Species specific MIC BP of 0.25/0.5mg/L applied to interpret susceptibility.